An IND goes into effect 30 days after FDA receives it unless the agency places the study on clinical hold. That milestone matters, but it is not the same as being ready to dose a first participant. First patient in depends on a set of operational workstreams that need to run in parallel, often starting well before the IND is submitted.
Emerging sponsors frequently plan to the IND and then discover that drug supply, site contracts and system builds still have months to go.
Which workstreams gate first patient?
Investigational product. Manufacturing, release testing, labeling, packaging and shipment to sites or depots, with temperature control where needed.
Study documents. Final protocol, investigator's brochure, consent templates, pharmacy and laboratory manuals.
Sites. Selection, contracts and budgets, ethics approval, pharmacy readiness and site initiation.
Systems. EDC build and user acceptance testing, randomization and supply management, eTMF and the safety database.
Vendors. Central and specialty laboratories, bioanalytical labs and any other specialty providers.
Safety processes. Safety management plan, serious adverse event reporting flow, medical monitoring and, for dose escalation, a safety review committee charter.
Essential documents. Investigator statements, financial disclosures and a trial master file ready to receive them.
Insurance. Clinical trial insurance, especially where sites or countries require it.
Why do these workstreams slip?
They are planned sequentially rather than in parallel. Owners are unclear in a small team. Long-lead items such as drug product and site contracts start late. And protocol changes after agency feedback ripple through every document, system and budget that depended on the earlier version.
How do you run them in parallel?
Build one integrated plan backward from the target first-patient date, with the critical path visible. Hold a short weekly readiness review that covers every workstream, not just the CRO's. Agree in advance which activities can start at risk, such as site contracting or EDC design before the IND is in effect, and document those decisions and their rationale.
What is a readiness review?
A formal go or no-go check before first site activation and again before first dose. It confirms that drug is released and on site, approvals are in place, systems are validated and live, staff are trained, safety processes are tested and essential documents are filed. Each item has a named owner who signs off. It sounds bureaucratic. In practice, it is the cheapest insurance a first study can buy.
What is the most common blind spot?
Drug supply. Manufacturing timelines, release testing and labeling for the clinic often run on a separate track managed by CMC colleagues, and clinical operations may learn of a delay only weeks before the planned first dose. Put investigational product on the same integrated plan as everything else, reviewed in the same meeting.
Keep reading: Getting Real Value From Your Pre-IND Meeting
